ENDPOINTS

Gilead deepens its stake in Assembly Biosciences; NGM licenses out MASH drug

5 months ago

News Briefing

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

5 months ago

Special

Pharma

Tessera gets up to $50M from the Gates Foundation; Tvardi’s reverse merger

5 months ago

News Briefing

Affimed’s early lung cancer data disappoint; Indapta's $22M round

5 months ago

News Briefing

Candid inks three T cell engager deals; PepGen trial put on hold

5 months ago

News Briefing

Eisai subsidiary nabs Japan rights for schizophrenia drug; Novavax's $50M milestone

5 months ago

News Briefing

Elevation to pay up to $368M in ADC deal; Bavarian Nordic closes San Diego site

5 months ago

News Briefing

BenevolentAI restructures; Cimeio, Kyowa ink cell therapy deal

5 months ago

News Briefing

CervoMed’s Phase 2 miss; NICE to cover Santhera’s Duchenne drug

5 months ago

News Briefing

Enanta's mid-stage win in pediatric RSV; Carisma to lay off 34% of staff

5 months ago

News Briefing

Teva to divest business venture in Japan; Layoffs at Rome Therapeutics

5 months ago

News Briefing

UK to limit access to Lilly’s Zepbound; VivaVision’s positive Phase 2

5 months ago

News Briefing

AstraZeneca's new EVP of international amid China investigation; Janux’s $300M offering

5 months ago

News Briefing

BMS inks deal with AI Proteins; Terns’ early-stage leukemia data

5 months ago

News Briefing

Senti Bio’s Phase 1 CAR-NK data; Allink raises $42M

5 months ago

News Briefing

Recursion reduces workforce; Oxford Nanopore teams up with UK Biobank

5 months ago

News Briefing

Aviceda aims to raise $200M; Nerviano gets back rights to PARP1 inhibitor

6 months ago

News Briefing

Replimune aims to raise $125M; Otsuka makes another deal with Ionis

6 months ago

News Briefing

Cidara's $100M PIPE; Pyxis Oncology's stock falls on Phase 1 data

6 months ago

News Briefing

Bayer, Cytokinetics make a deal in Japan; Ex-Carmot CEO to run LB Pharmaceuticals

6 months ago

News Briefing

Aclaris makes a deal, aims to raise $80M; Emmecell’s Ph1 update in corneal edema

6 months ago

News Briefing

Vitalli ends work on Daewoong asset; Alector’s $50M loan

6 months ago

News Briefing

ALX Oncology hires Genentech, Mirati vet as CMO; After Carmot, Heather Turner has three new roles on tap

6 months ago

Peer Review

Zai Lab aims to raise $200M; Kronos Bio to seek ‘strategic’ options

6 months ago

News Briefing

about the author

author articles

Gilead deepens its stake in Assembly Biosciences; NGM licenses out MASH drug

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Tessera gets up to $50M from the Gates Foundation; Tvardi’s reverse merger

Affimed’s early lung cancer data disappoint; Indapta's $22M round

Candid inks three T cell engager deals; PepGen trial put on hold

Eisai subsidiary nabs Japan rights for schizophrenia drug; Novavax's $50M milestone

Elevation to pay up to $368M in ADC deal; Bavarian Nordic closes San Diego site

BenevolentAI restructures; Cimeio, Kyowa ink cell therapy deal

CervoMed’s Phase 2 miss; NICE to cover Santhera’s Duchenne drug

Enanta's mid-stage win in pediatric RSV; Carisma to lay off 34% of staff

Teva to divest business venture in Japan; Layoffs at Rome Therapeutics

UK to limit access to Lilly’s Zepbound; VivaVision’s positive Phase 2

AstraZeneca's new EVP of international amid China investigation; Janux’s $300M offering

BMS inks deal with AI Proteins; Terns’ early-stage leukemia data

Senti Bio’s Phase 1 CAR-NK data; Allink raises $42M

Recursion reduces workforce; Oxford Nanopore teams up with UK Biobank

Aviceda aims to raise $200M; Nerviano gets back rights to PARP1 inhibitor

Replimune aims to raise $125M; Otsuka makes another deal with Ionis

Cidara's $100M PIPE; Pyxis Oncology's stock falls on Phase 1 data

Bayer, Cytokinetics make a deal in Japan; Ex-Carmot CEO to run LB Pharmaceuticals

Aclaris makes a deal, aims to raise $80M; Emmecell’s Ph1 update in corneal edema

Vitalli ends work on Daewoong asset; Alector’s $50M loan

ALX Oncology hires Genentech, Mirati vet as CMO; After Carmot, Heather Turner has three new roles on tap

Zai Lab aims to raise $200M; Kronos Bio to seek ‘strategic’ options